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High platelet reactivity
Tailored antiplatelet therapyHigh platelet reactivity (HPR) during dual antiplatelet therapy is a marker of vascular risk, in particular stent
thrombosis in patients with acute coronary syndromes. Genetic determinants (CYP2C19*2 polymorphism),
advanced age, female gender, diabetes and reduced ventricular function are related to a higher risk to develop
HPR. In addition, inﬂammation and increased platelet turnover, as revealed by the elevated percentage of
reticulate platelets in patients' blood that characterize the acute phase of ACS, are associated with HPR. To
overcome the limitation of Clopidogrel, new antiplatelet agents (Prasugrel and Ticagrelor) were synthesized
and the demonstration of their superiority over Clopidogrel was obtained in two randomized trials TRITON
TIMI 38 and PLATO. Due to the current possibility of choosing betweenmultiple antiplatelet strategies, the future
prospect is to include the deﬁnition of platelet function during treatment in order to set a tailored therapy, in
addition to clinical data and classical risk factors.
© 2014 Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Speaking of the possible usefulness of platelet aggregation tests in
clinical practice means telling a story that began with many question
marks and that has arrived at the deﬁnition of the existence of platelet
hyper-reactivity due to ADP and its potential clinical role [2], in a
document of “consensus” [1].
The functionality of platelets can be measured through aggregation
induced by various agonists, ﬁrst of all, the ADP target of
thienopyridines and arachidonic acid, which is mainly inﬂuenced by
the recruitment of acetylsalicylic acid. The “gold standard” method is
represented by the aggregation of platelets on platelet-rich plasma.
There are also numerous systems, which consent measurement of the
aggregation on whole blood, the so-called “point of care” because of
its potential usefulness at patient's bedside [3].
First of all, it is essential to deﬁne the clinical setting in which the
majority of the evidence has been accumulated in this ﬁeld: the
acute phase of patients with acute coronary syndrome undergoing
percutaneous revascularization with stent implantation, or the “fate”
treatment of the majority of patients with acute coronary syndrome in
2012.
In this clinical context, a considerable number of studies have shown
that the presence of ADP platelet hyperreactivity is associated with
a signiﬁcantly increased risk of ischemic events, ﬁrst of all, of stent
thrombosis, myocardial infarction and cardiac death.
Our group has demonstrated this in 804 patients undergoing drug-
eluting stent implantation with a 6-month follow-up in the RECLOSE
trial [4].is an open access article under the CConﬁrmation was obtained in a population at particularly high risk
such as patients undergoing stenting for unprotected leftmain coronary
artery disease, in which platelet hyperreactivity by ADP was associated
with an increased risk of ischemic events in a follow-up of three years
[5]. There are also data that have correlatedADP platelet hyperreactivity
and events by measuring the platelet hyperreactivity with point of
care methods such as Multiplate and Verify-Now [6,7]. These methods
appear to be of particular clinical utility because they render
the measurement of platelet function possible at the bedside and,
potentially, in the cath lab.
More recently, we conducted a prospective cohort study of 1,789 con-
secutive patients with acute coronary syndrome undergoing
percutaneous revascularization procedure in which platelet function
was assessed prospectively after clopidogrel loading and the antithrom-
botic treatment adjusted according to the results of the functional test [8].
Patients with platelet hyperreactivity determined by the presence of
platelet aggregation induced byADPN 70% received an increased dose of
clopidogrel or were treated with ticlopidine on the base of the ADP test.
Results have documented that (1) after loading 600 mg of
clopidogrel in patients with acute coronary syndrome undergoing
invasive procedure, ADP platelet hyperreactivity incidence is relatively
low (14%); (2) platelet aggregation remains at high levels (N70%) in
38% of patients after adjustment with ﬁrst-generation thienopyridine;
and (3) platelet hyper-reactivity after clopidogrel loading is associated
with an increased risk of ischemic events in short and long term.
What are the possible causes of this ADP platelet hyperreactivity?
(Fig. 1). Clopidogrel is a prodrug: only 15% of the administered drug is
converted into active metabolites by the cytochrome P4509 enzymesC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.
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encoding these enzymes, and almost contemporaneously, several re-
search groups have shown the role of polymorphism CYP2C19 * 2 in in-
creasing the risk of platelet hyperreactivity and, especially, clinical
events [9,10].
Carriers of this polymorphism in heterozygous or homozygous form
have an enzyme that works in a reducedmanner and, therefore, are at a
higher risk of maintaining a persistent platelet reactivity despite
treatment. Consequently, carriers of this polymorphism have an
increased risk of adverse ischemic events, from stent thrombosis to
cardiovascular death. These data were summarized and proven by the
more extensivemeta-analysis thatwe published at the endof 2010 [11].
Hence, does genotype really explain the entire association between
platelet hyperreactivity and adverse events? The truth in medicine is,
as usual, much more complex. We know that the extent of inhibition
of platelet function by ADP remains a risk marker of adverse events
even within a population that is not carrying the CYP2C19*2 polymor-
phism and is therefore able to properly metabolize clopidogrel [12].
Possible explanations for this are related to the existence of genetic
determinants not yet known, or the presence of other “non-genetic”
determinants of hyperreactivity. Advanced age, female sex, diabetes,
and reduced left ventricular systolic function are the clinical conditions
associatedwith an increased platelet reactivity and thus to an increased
risk of inadequate inhibition of platelet function during standard
treatment [13].Fig. 2.The population of diabetic patients with a particularly increased risk
of ischemic events is the group which has been most studied: the
condition associated with platelet hyperactivity disease explains the
increased prevalence of platelet hyperactivity by ADP in this group of
patients. It should also be emphasized that the “answer” to aspirin
could be modiﬁed in this population, and this mechanism has been
invoked as a possible explanation for aspirin's lack of effect in reducing
cardiovascular events in primary prevention.
There is also a potential interaction between clopidogrel and drugs
metabolized by cytochrome P450 [14]. This aspect was revealed for
the ﬁrst time in ex vivo studies, which have shown how omeprazole,
the proton pump inhibitor (PPI) most widely used in clinical medicine,
is associatedwith a reduction in the effect of platelet function inhibition
induced by ADP-mediated clopidogrel. It was not entirely clearwhether
this is an effect of the drug or class, since in all clinical trials, the number
of patients taking omeprazole is much higher than other PPIs.
Ex vivo studies show that pantoprazole, which follows a different
metabolic pathway than other PPIs, does not interfere with the platelet
inhibition of clopidogrel [15]. If the effect on platelet function translates
into an increased risk of clinical events, it is clear from Hulot's most
recent meta-analysis, on the basis of which the intake of PPIs together
with clopidogrel signiﬁcantly increases the risk of ischemic events [16].
A particularly important aspect of the possible existence of acquired
determinants of platelet hyperreactivity is the role of the “acute phase”:
it has been shown how the inﬂammatory movement and increased
platelet turnover that characterize the acute phase of ACS is associated
with increased platelet reactivity and an increased risk of hyperreactiv-
ity during therapy. We see this clearly when using simple markers of
inﬂammation such as white blood cells and ESR14, as well as through
elegant studies showing how cytochemical pro/anti-inﬂammation
balance is all shifted in favor of pro-inﬂammatory cytokines in patients
with platelet hyperreactivity [17].
Moreover, the number of reticulatedplatelets, the youngest platelets
released into the circulation from themarrow andmost mRNA content,
and which represent a measure of the increased platelet turnover, are
higher in patients with platelet hyperreactivity during therapy [18].
Moving from the lab to the individual patient, we can observe the
effect of the acute phase even in individual patients: in fact, we have
shown that moving away from the acute phase and rechecking
our patients after 1 and 6months, the proportion of patientswith signif-
icantly decreased platelet hyperreactivity suggests that the shutdown of
the movements related to the acute phase signiﬁcantly reduced the
degree of platelet reactivity and therefore the percentage of patients
with an inadequate inhibition.
An indirect conﬁrmation of this comes from the results of the
CURRENT-OASIS 7 [19]where in the population exposed to PCI, patients
randomized to receive a higher dose of clopidogrel in the ﬁrst week of
treatment were those who experienced a signiﬁcant lower number of
ischemic events. This suggests that a more intensive treatment in the
acute phase would be able to better protect patients.
What to do with patients presenting platelet hyperreactivity?
The ﬁrst attempt was to intensify therapy with clopidogrel by doubling
the dose in pre-prasugrel and pre-ticagrelor eras. This was the attempt
tested by the GRAVITAS trial [20], which randomized patients undergo-
ing drug-eluting stent implantation and hyperreactivity demonstrated
with Verify Now method to standard treatment of clopidogrel versus
doubled dose (150 mg/day). After 6 months, no statistically signiﬁcant
difference was demonstrated between the two treatment groups for is-
chemic end points. The analysis of data showed that mostly stable pa-
tients (60%) were enrolled and only 0.5% of patients with STEMI;
therefore, patients who were different from those in which the role of
ADP platelet hyperreactivity platelet had been demonstrated.
Furthermore, data concerning the control of platelet function
performed at 1 and 6 months demonstrated how, even in the doubled
dose group, as many as 40% of patients showed a persistent platelet re-
activity that had not been corrected by the adjustment of the
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tensive treatment was the lack of increase in bleeding between the
two groups undergoing treatment. On the other hand, all patients who
experienced an ischemic event had higher platelet reactivity that was
very close to the chosen hyperreactivity cut-off.
One area of research that still awaits studies in literature is the
possible role of platelet hyperreactivity by different agonists, not only
ADP but also arachidonic acid and collagen.
In several case studies, but in over 1,000 patients, data of our group
[21,22] have shown how global platelet hyperreactivity, both ADP as
well as arachidonic acid and collagen, is the true marker of risk of
adverse events, identifying the true “aggressive” platelet and “vulnera-
ble” patient requiring personalized treatment.
The perspective is to include the deﬁnition of platelet function
during treatment in order to better stratify our revascularized SCA
patients with stent implantation, in addition to classic risk factors
and procedural requirements.
Another fascinating area for future research concerns the most
recent data of a possible correlation between excessive inhibition of
platelet function during treatment and risk of bleeding. The current
and future possibility of choosing between anti-platelet strategies
makes policies using the measurement of platelet function, in addition
to clinical data as a means of selecting and customizing treatment,
even more appropriate.
References
[1] Bonello L, Tantry US, Marcucci R, et al. Working Group on High On-Treatment
Platelet Reactivity. Consensus and future directions on the deﬁnition of high
on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol
2010;56:919–33.
[2] Soﬁ F, Marcucci R, Gori AM, et al. Clopidogrel non-responsiveness and risk of cardio-
vascular morbidity. An updated meta-analysis. Thromb Haemost 2010;2:103–10.
[3] Paniccia R, Antonucci E, Maggini N, et al. Comparison of methods for monitoring
residual platelet reactivity after clopidogrel by point-of-care tests on whole blood
in high-risk patients. Thromb Haemost 2010;104:287–92.
[4] Buonamici PG, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after
clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol
2007;24:2312–7.
[5] Migliorini A, Valenti R, Marcucci R, et al. High residual platelet reactivity after
clopidogrel loading and long-term clinical outcome after drug eluting stenting for
unprotected left main coronary disease. Circulation 2009;120:2214–21.
[6] Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial
infarction in acute coronary syndrome patients receiving coronary stenting are
predicted by residual platelet reactivity to ADP detected by a point-of-care assay.
A 12-month follow-up. Circulation 2009;119:237–42.[7] Sibbing D, Braun S, Jawansky S, et al. Assessment of ADP-induced platelet aggregation
with light transmission aggregometry and multiple electrode platelet aggregometry
before and after clopidogrel treatment. Thromb Haemost 2008;99:121–6.
[8] Parodi G, Marcucci R, Valenti R, et al. High residual platelet reactivity after
clopidogrel loading and long-term cardiovascular events among patients with
acute coronary syndromes undergoing PCI. JAMA 2011;306(11):1215–23.
[9] Giusti B, Gori AM, Marcucci R, et al. Relation of cytochrome P450 2C19 loss-of-
function polymorphism to occurrence of drug-eluting coronary stent thrombosis.
Am J Cardiol 2009;103:806–11.
[10] Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response
to clopidogrel. N Engl J Med 2009;360:354–62.
[11] Mega JL, Simon T, Collet JP, et al. Reduced function CYP2C19 genotype and risk of
adverse clinical outcomes among patients treated with clopidogrel predominantly
for PCI. JAMA 2010;304:1821–30.
[12] Marcucci R, Guisti B, Paniccia R, et al. High on treatment platelet reactivity by ADP
and increate risk of MACE in good clopidogrel metabolizers. Platelets 2012 Mar 5.
[13] Marcucci R, Gori AM, Paniccia R, et al. Residual platelet reactivity is associated with
clinical and laboratory characteristics in patients with ischemic heart disease under-
going PCI on dual antiplatelet therapy. Atherosclerosis 2007;195:217–23.
[14] Simon T, Steg PG, Gilard M, et al. Clinical events as a function of proton pump
inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large
nationwide cohort of acute myocardial infarction: results from the French Registry
of Acute ST-Elevation and Non-ST Elevation Myocardial Infarction (FAST-MI)
registry. Circulation 2011;123:474–82.
[15] Fontes-Carvalho R, Albuquerque A, Araújo C, et al. Omeprazole, but not
pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical
crossover trial in patients after myocardial infarction evaluating the clopidogrel-
PPIs drug interaction. Eur J Gastroenterol Hepatol 2011 May;23(5):396–404.
[16] Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogreltreated patients
according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhib-
itor coadministration: a systematic metaanalysis. J Am Coll Cardiol 2010 Jul 6;56(2):
134–43.
[17] Gori AM, Cesari F, Marcucci R, et al. The balance between pro- and anti-inﬂammatory
cytokines is associated with platelet aggregability in acute coronary syndrome
patients. Atherosclerosis 2009 Jan;202(1):255–62.
[18] Cesari F, Marcucci R, Caporale R, et al. Relationship between high platelet turnover
and platelet function in high-risk patients with coronary artery disease on dual
antiplatelet therapy. Thromb Haemost 2008;99:930–5.
[19] Mehta SR, Tanguay JF, Eikelboom JW, et al. CURRENT-OASIS 7 trial investigators.
Double-dose versus standard-dose clopidogrel and highdose versus low-dose
aspirin in individuals undergoing percutaneous coronary intervention for acute
coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet
2010;376:1233–43.
[20] Price MJ, Berger PB, Teirstein PS, et al. GRAVITAS Investigators. Standard- vs high-
dose clopidogrel based on platelet function testing after percutaneous coronary
intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097–105.
[21] Gori AM, Marcucci R, Migliorini A, et al. Incidence and clinical impact of dual
nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents.
J Am Coll Cardiol 2008 Aug 26;52(9):734–9.
[22] Marcucci R, Gori AM, Paniccia R, et al. High on-treatment platelet reactivity by more
than one agonist predicts 12-month follow-up cardiovascular death and non-fatal
myocardial infarction in acute coronary syndrome patients receiving coronary
stenting. Thromb Haemost 2010 Aug;104(2):279–86.
